Remus Pharmaceuticals Limited

REMUS

INE0O5T01011

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 07:43:53 2024-05-31 am EDT			5-day change	1st Jan Change
7,431 ^INR	+3.19%		-2.43%	-2.91%

May. 31	790,000 Equity Shares of Remus Pharmaceuticals Limited are subject to a Lock-Up Agreement Ending on 31-MAY-2024.	CI
May. 16	Remus Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2024	CI

Remus Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2024

May 16, 2024 at 05:09 am EDT

Remus Pharmaceuticals Limited reported earnings results for the full year ended March 31, 2024. For the full year, the company reported sales was INR 2,125 million. Revenue was INR 2,178.99 million.

Net income was INR 215.37 million. Basic earnings per share from continuing operations was INR 152.01. Diluted earnings per share from continuing operations was INR 152.01.

Latest news about Remus Pharmaceuticals Limited

790,000 Equity Shares of Remus Pharmaceuticals Limited are subject to a Lock-Up Agreement Ending on 31-MAY-2024.	May. 30	CI
Remus Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2024	May. 16	CI
Remus Pharmaceuticals Limited Declare Second Interim Dividend for the Financial Year 2023-24	Apr. 23	CI
Remus Pharmaceuticals Limited Announces Setting Up of Branch Office in Dubai	Feb. 07	CI
Remus Pharmaceuticals Limited entered into a Memorandum of Understanding to acquire a 51% stake in Espee Biopharma & Finechem LLC for $2.7 million.	23-09-14	CI
Remus Pharmaceuticals Limited has completed an IPO in the amount of INR 476.852 million.	23-05-23	CI
Remus Pharmaceuticals Limited Reports Earnings Results for the Nine Months Ended December 31, 2022	23-03-13	CI
Remus Pharmaceuticals Limited has filed an IPO.	23-03-10	CI

Chart Remus Pharmaceuticals Limited

Duration

Period

More charts

Remus Pharmaceuticals Limited is engaged in marketing and distribution of finished formulations of pharmaceutical drugs. The Company also deals in active pharmaceutical ingredient (API). It also provides technical consultancy services to various distributors for preparation of reports on the dossiers of the products to be registered by them in various countries. It deals in drug forms like capsules, cream, eye drops, gel, infusion, inhalation, inhaler, injection, nail lacquer, nasal solution, nasal spray, nebulizer, ointment, ophthalmic, oral gel, oral solution, oral suspension, sachet, suspension, tablet. The therapeutic areas it works include oncology, cardiovascular, anti-diabetic, immune suppressants, anti-biotic, antibacterial, dermatology, central nervous system, and others. Its oncology products include Sorafenib Tablets, Enzalutamide Capsules, Lenalidomide Capsule, and others. Its cardiovascular products include Rivaroxaban Tablets, Ticagrelor Tablets, and others.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
REMUS PHARMACEUTICALS LIMITED	-2.91%	131M
ELI LILLY AND COMPANY	+40.73%	739B
NOVO NORDISK A/S	+32.83%	598B
JOHNSON & JOHNSON	-6.30%	353B
MERCK & CO., INC.	+15.15%	318B
ABBVIE INC.	+4.05%	285B
ASTRAZENECA PLC	+15.00%	240B
NOVARTIS AG	+9.78%	210B
ROCHE HOLDING AG	-5.52%	206B
AMGEN INC.	+6.17%	164B